[{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Positive Top-Line Results for Two Comparative Studies for AVT02, a Proposed Biosimilar to HUMIRA\u00ae (Adalimumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces that the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to Humira\u00ae (Adalimumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Completes Second Round of a US$100 Million Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Reaches Primary Completion Date in Its Switching Study for AVT02","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara\u00ae (ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara\u00ae (ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"ATP Holdings","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alvotech Completes $100 Million Convertible Bond Private Placement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara\u00ae (ustekinumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ICELAND","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Alvotech"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Jamteki (ustekinumab) is a monoclonal antibody and a biosimilar candidate to Stelara® (ustekinumab). Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses.
AVT04 (ustekinumab) is a monoclonal antibody and a biosimilar candidate to Stelara® (ustekinumab). Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses.
The net proceeds will be used for the continued development of its biosimilars pipeline, including AVT04, a monoclonal antibody, a biosimilar candidate to Stelara (ustekinumab).
The agreement grants a license entry date for AVT04, Alvotech’s proposed biosimilar to Stelara® (ustekinumab), in the United States. Ustekinumab is a monoclonal antibody and binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses.
AVT04 (ustekinumab) is a monoclonal antibody and a biosimilar candidate to Stelara® (ustekinumab). Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses.
AVT04 (Ustekinumab) is a monoclonal antibody and a biosimilar candidate to Stelara® (ustekinumab). Ustekinumab binds to two cytokines, IL-12 and IL-23, that are involved in inflammatory and immune responses.
Results from pharmacokinetic similarity study demonstrate bioequivalence of AVT04 (ustekinumab), a human IgG1k monoclonal antibody that binds with specificity to p40 protein subunit used by both interleukin-12 and interleukin-23 cytokines to reference product Stelara.
AVT02-GL0302 is a multicenter, randomized, double-blind, parallel-group study to evaluate PK, efficacy, safety & immunogenicity between patients receiving Humira and patients undergoing repeated switches between Humira and AVT02, followed by an optional safety Extension Phase.
Proceeds will be used for the development of companies lead drug AVT02. As part of the first round Shinhan from Korea, Baxter Healthcare SA from the US and ATHOS (Strüngmann Family Office) from Germany invested in Alvotech.
AVT02 is a proposed biosimilar of HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms that are expected to be beneficial to patients and to be differentiated from most biosimilar competitors, while matching the newest dosage forms of the reference product.